D-0115-2026 Class II Ongoing
FDA drug recall D-0115-2026 was initiated by ProRx LLC on Oct 15, 2025 and is designated Class II. Reason for recall: Lack of Assurance of Sterility The recall status is ongoing. Affected quantity: 8,400 vials.
Recall details
- Product Type
- Drugs
- Report Date
- Nov 5, 2025
- Initiation Date
- Oct 15, 2025
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 8,400 vials
Product description
Semaglutide Injection, 10 mg/4 mL (2.5 mg/mL), 4mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-225-04
Reason for recall
Lack of Assurance of Sterility
Distribution pattern
TX and UT
Code information
Lot, Best Use Date (BUD): Lot PRORX050925-1, BUD November 4, 2025; Lot ProRx051425-5, BUD November 10, 2025; Lot ProRx051425-6, BUD November 10, 2025
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0115-2026
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026